Mitophagy–NLRP3 Inflammasome Crosstalk in Parkinson’s Disease: Pathogenic Mechanisms and Emerging Therapeutic Strategies
International Journal of Molecular Sciences · 03.01.2026 · 27 (1) · 486
DOI: 10.3390/ijms27010486 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.01.2026. Verfasst von Sahabuddin Ahmed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Mitophagy, Parkinson Disease, Inflammasomes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and pathological α-synuclein aggregation. Growing evidence identifies chronic neuroinflammation—particularly NLRP3 inflammasome activation in microglia—as a central driver for PD onset and progression. Misfolded α-synuclein, mitochondrial dysfunction, and environmental toxins act as endogenous danger signals that prime and activate NLRP3 inflammasome, leading to caspase-1–mediated maturation of IL-1β and IL-18 and subsequent pyroptotic cell death. Impaired mitophagy, due to defects in PINK1/Parkin pathways or receptor-mediated mechanisms, permits accumulation of dysfunctional mitochondria and release DAMPs, thereby amplifying NLRP3 activity. Studies demonstrate that promoting mitophagy or directly inhibiting NLRP3 attenuates neuroinflammation and protects dopaminergic neurons in PD models. Autophagy-inducing compounds, along with NLRP3 inhibitors, demonstrate neuroprotective potential, though their clinical translation remains limited due to poor blood–brain barrier penetration, off-target effects, and insufficient clinical data. Additionally, the context-dependent nature of mitophagy underscores the need for precise therapeutic modulation. This review summarizes current understanding of inflammasome–mitophagy crosstalk in PD, highlights major pharmacological strategies under investigation, and outlines its limitations. Future progress requires development of specific modulators, targeted delivery systems, and robust biomarkers of mitochondrial dynamics and inflammasome activity for slowing PD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA.
- Independent Researcher, New Haven, CT 06511, USA.
ORCID-Profile: Sahabuddin Ahmed
Zitieren
APA
Ahmed, S., Pasam, T., & Afreen, F. (2026). Mitophagy–NLRP3 Inflammasome Crosstalk in Parkinson’s Disease: Pathogenic Mechanisms and Emerging Therapeutic Strategies. International Journal of Molecular Sciences, 27(1), 486. https://doi.org/10.3390/ijms27010486
Vancouver
Ahmed S, Pasam T, Afreen F. Mitophagy–NLRP3 Inflammasome Crosstalk in Parkinson’s Disease: Pathogenic Mechanisms and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 2026;27(1):486. doi:10.3390/ijms27010486
BibTeX
@article{Ahmed2026,
author = {Ahmed, Sahabuddin and Pasam, Tulasi and Afreen, Farzana},
title = {Mitophagy–NLRP3 Inflammasome Crosstalk in Parkinson’s Disease: Pathogenic Mechanisms and Emerging Therapeutic Strategies},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {1},
pages = {486},
doi = {10.3390/ijms27010486}
}
EUVIMED